The IVIG/plasma marketplace seems relatively stable at this time, despite a history of supply issues, rampant off-label use, and attempts at consolidation within the space. The PGR network reports slow and steady growth across the major players - BAX, CSL Behring, and TLCR, although parts appear to be moving in the direction of a major ramp-up.

Of the products currently available, subcutaneous formulations continue to gain share, but the true potential for the market lies in the ability of these products to treat neurological disorders, such as Alzheimer’s. Until this indication is granted FDA approval, insurance companies will attempt to contain costs from high volume off-label use. BAX, CSL Behring, and Talecris/Grifolz have all made efforts to expand their sales forces and ensure that product is available in the hope that when it is approved for Alzheimers they will be able to reap the rewards.

Tweet This Post